Cambridge Investment Research Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.9M | Buy |
21,946
+5,991
| +38% | +$2.66M | 0.02% | 636 |
|
|
2026
Q1 | $7.12M | Buy |
15,955
+1,598
| +11% | +$745K | 0.02% | 772 |
|
|
2025
Q4 | $6.51M | Buy |
14,357
+240
| +2% | +$103K | 0.02% | 786 |
|
|
2025
Q3 | $5.53M | Sell |
14,117
-3,212
| -19% | -$1.34M | 0.02% | 855 |
|
|
2025
Q2 | $7.71M | Buy |
17,329
+998
| +6% | +$460K | 0.02% | 652 |
|
|
2025
Q1 | $7.92M | Buy |
16,331
+3,750
| +30% | +$1.75M | 0.03% | 594 |
|
|
2024
Q4 | $5.07M | Sell |
12,581
-1,936
| -13% | -$897K | 0.02% | 801 |
|
|
2024
Q3 | $6.75M | Buy |
14,517
+594
| +4% | +$285K | 0.02% | 654 |
|
|
2024
Q2 | $6.53M | Sell |
13,923
-4,752
| -25% | -$2.06M | 0.02% | 635 |
|
|
2024
Q1 | $7.81M | Buy |
18,675
+2,813
| +18% | +$1.19M | 0.03% | 550 |
|
|
2023
Q4 | $6.45M | Buy |
15,862
+2,803
| +21% | +$1.04M | 0.03% | 580 |
|
|
2023
Q3 | $4.54M | Buy |
13,059
+21
| +0.2% | +$7.34K | 0.02% | 701 |
|
|
2023
Q2 | $4.59M | Buy |
13,038
+455
| +4% | +$153K | 0.02% | 707 |
|
|
2023
Q1 | $3.96M | Sell |
12,583
-874
| -6% | -$262K | 0.02% | 750 |
|
|
2022
Q4 | $3.89M | Sell |
13,457
-995
| -7% | -$303K | 0.02% | 718 |
|
|
2022
Q3 | $4.18M | Buy |
14,452
+450
| +3% | +$129K | 0.02% | 647 |
|
|
2022
Q2 | $3.95M | Buy |
14,002
+1,055
| +8% | +$282K | 0.02% | 694 |
|
|
2022
Q1 | $3.38M | Buy |
12,947
+758
| +6% | +$180K | 0.02% | 847 |
|
|
2021
Q4 | $2.68M | Sell |
12,189
-45
| -0.4% | -$8.75K | 0.01% | 976 |
|
|
2021
Q3 | $2.22M | Sell |
12,234
-1,038
| -8% | -$203K | 0.01% | 1043 |
|
|
2021
Q2 | $2.68M | Buy |
13,272
+1,093
| +9% | +$229K | 0.01% | 960 |
|
|
2021
Q1 | $2.62M | Buy |
12,179
+2,923
| +32% | +$642K | 0.01% | 874 |
|
|
2020
Q4 | $2.19M | Buy |
9,256
+434
| +5% | +$99.6K | 0.01% | 879 |
|
|
2020
Q3 | $2.4M | Sell |
8,822
-13,026
| -60% | -$3.59M | 0.02% | 719 |
|
|
2020
Q2 | $6.34M | Buy |
21,848
+11,228
| +106% | +$3.04M | 0.05% | 367 |
|
|
2020
Q1 | $2.53M | Buy |
10,620
+2,067
| +24% | +$474K | 0.02% | 572 |
|
|
2019
Q4 | $1.87M | Buy |
8,553
+1,175
| +16% | +$238K | 0.01% | 823 |
|
|
2019
Q3 | $1.25M | Sell |
7,378
-20
| -0.3% | -$3.54K | 0.01% | 958 |
|
|
2019
Q2 | $1.36M | Buy |
7,398
+54
| +0.7% | +$9.44K | 0.01% | 889 |
|
|
2019
Q1 | $1.35M | Buy |
7,344
+281
| +4% | +$51.9K | 0.01% | 889 |
|
|
2018
Q4 | $1.17M | Sell |
7,063
-399
| -5% | -$69.1K | 0.01% | 853 |
|
|
2018
Q3 | $1.44M | Buy |
7,462
+1,451
| +24% | +$258K | 0.01% | 821 |
|
|
2018
Q2 | $1.02M | Buy |
6,011
+70
| +1% | +$10.9K | 0.01% | 959 |
|
|
2018
Q1 | $968K | Sell |
5,941
-383
| -6% | -$62.6K | 0.01% | 957 |
|
|
2017
Q4 | $948K | Sell |
6,324
-1,301
| -17% | -$193K | 0.01% | 931 |
|
|
2017
Q3 | $1.16M | Buy |
7,625
+1,242
| +19% | +$187K | 0.02% | 777 |
|
|
2017
Q2 | $823K | Buy |
6,383
+101
| +2% | +$12.2K | 0.01% | 905 |
|
|
2017
Q1 | $687K | Sell |
6,282
-18
| -0.3% | -$1.58K | 0.01% | 914 |
|
|
2016
Q4 | $464K | Sell |
6,300
-4
| -0.1% | -$325 | 0.01% | 1051 |
|
|
2016
Q3 | $550K | Sell |
6,304
-384
| -6% | -$36.3K | 0.01% | 979 |
|
|
2016
Q2 | $575K | Buy |
6,688
+136
| +2% | +$11.8K | 0.01% | 872 |
|
|
2016
Q1 | $521K | Sell |
6,552
-1,292
| -16% | -$117K | 0.01% | 873 |
|
|
2015
Q4 | $987K | Sell |
7,844
-611
| -7% | -$73.8K | 0.02% | 552 |
|
|
2015
Q3 | $881K | Sell |
8,455
-2,984
| -26% | -$383K | 0.03% | 522 |
|
|
2015
Q2 | $1.41M | Buy |
11,439
+3,543
| +45% | +$446K | 0.04% | 402 |
|
|
2015
Q1 | $931K | Sell |
7,896
-555
| -7% | -$66.5K | 0.03% | 527 |
|
|
2014
Q4 | $1M | Sell |
8,451
-940
| -10% | -$106K | 0.03% | 479 |
|
|
2014
Q3 | $1.05M | Buy |
9,391
+1,080
| +13% | +$103K | 0.03% | 500 |
|
|
2014
Q2 | $787K | Sell |
8,311
-938
| -10% | -$65.8K | 0.03% | 539 |
|
|
2014
Q1 | $654K | Sell |
9,249
-4,763
| -34% | -$377K | 0.02% | 579 |
|
|
2013
Q4 | $1.04M | Sell |
14,012
-2,443
| -15% | -$170K | 0.04% | 386 |
|
|
2013
Q3 | $1.25M | Buy |
16,455
+148
| +0.9% | +$11.8K | 0.05% | 314 |
|
|
2013
Q2 | $1.31M | Buy |
+16,307
| New | +$1.2M | 0.07% | 265 |
|
Other funds holding VRTX
Cambridge Investment Research Advisors's VRTX Position: Q2 2026 in Review
Cambridge Investment Research Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 38% in Q2 2026, buying an estimated $2.66M and bringing the position to 21,946 shares worth $10.9M. The position accounts for 0.02% of the portfolio, ranked #636.
Cambridge Investment Research Advisors first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Cambridge Investment Research Advisors held 21,946 shares of Vertex Pharmaceuticals worth $10.9M as of Q2 2026.
- Cambridge Investment Research Advisors bought 5,991 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.66M.
- Vertex Pharmaceuticals made up 0.02% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #636 holding.
- Cambridge Investment Research Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.